Stocks-TAK-Takeda Pharmaceutical Co Ltd-ADR

TAK Takeda Pharmaceutical Co Ltd-ADR

0 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/3/2023: Takeda Pharmaceutical Co Ltd-ADR's revenues decreased by 6.43% and amounted to 29.72B. Net income increased by 14.22% to 2.34B. Net assets increased by 1.97% to 47.75B and EPS increased from 0.65 to 0.75.
TAK's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
52.34%
Net Profit Margin
6.77%
Operating Margin
11.07%
Return On Investment
2.19%